Book Value per Share: MorphoSys (MOR)

MorphoSys AG is investing in the global promotion of pelzaresib through B2B agreements. The book value per share illustrates this resilience, where -1.87 shows the value of this parameter. Drug integrity is guaranteed by a strict temperature-controlled transportation regime. The company is currently optimizing external production to eliminate disruptions in drug manufacturing.

MOR (MorphoSys Corp) Book Value per Share history from 07/04/2022 to 08/10/2024

Summary analytical data breakdowns for morphosys.com (MOR)

- price and consensus price forecast:

Price Chart MorphoSys Corp|MOR - Fair Value Consensus

- market capitalization data:

Market Capitalization MorphoSys AG|MOR - Real Price to Acquire Entire Company

- book capitalization data:

Book Value per Share MorphoSys|MOR - Book Capitalization|Market Value to Book Value Ratio morphosys.com|MOR - Total Business Assets

- debt and liquidity data:

Total Debt to Capital MorphoSys AG|MOR - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital MorphoSys|MOR - Company Cumulative Debt|Debt to Book Capitalization Ratio MorphoSys AG

Fundamental company valuation:MOR MorphoSys Corp

Book value per share determines the portion of net assets available to an investor upon business liquidation, serving as a defensive barrier against total capital loss. Analyzing the projected book value per share for MorphoSys AG (MOR) on GURU.Markets reveals how ownership of the HuCAL library and partner royalties capitalize intellectual property, creating fundamental stability for MorphoSys AG (MOR) within the biotechnology sector.

Competitor analysis

Net Assets per Single Share BeiGene Corp (ONC)|HALO - Accounting Value of a Share|RVMD (Revolution Medicines) - Book Value per Share|ascentage.com (AAPG) - Accounting Value per Share|CGON (CG Oncology) - Book Value per Share|Book Value per Share URGN|Net Assets per Single Share Bicara Bio BCAX|Equity per Share Personalis Genomics (PSNL)|Erasca, Inc. - Book Value per Share|Accounting Value per Share delcath.com DCTH|YMAB (Y-mAbs Therapeutics, Inc.) - Book Value per Share|AURA: Net Asset Value per Share|Net Assets per Single Share candeltx.com CADL|Accounting Value of a Share Accuray, Inc.|SLS - Accounting Value per Share|Accounting Value of a Share actuatetherapeutics.com|Book Value per Share CTOR (Citius Oncology)|Accounting Value per Share tuhurabio.com HURA|Accounting Value per Share TARA (Protara)|Fate Pharma - Book Value per Share|Net Assets per Single Share Aadi Bio (WHWK)|TCRX - Accounting Value of a Share|Book Value per Share CSBR|XBIT (XBiotech) - Net Asset Value per Share|Net Assets per Single Share CVM|Accounting Value per Share OSTX|Radiopharm Theranostics Limited - Net Assets per Single Share|Net Asset Value per Share ARTV (artivabio.com)|Net Assets per Single Share Adlai Nortye|Veru Inc - Accounting Value of a Share|Net Assets per Single Share Tempest Tx|XLO - Share Book Value|Book Value per Share renovarobio.com RENB|MURA (Mural Oncology) - Accounting Value of a Share|Net Assets per Single Share KAPA (Kairos Pharma Limited)|Net Asset Value per Share OKUR|GDTC (CytoMed Therapeutics) - Net Assets per Single Share|Net Assets per Share curis.com CRIS|APLM: Accounting Value per Share|tharimmune.com - Net Asset Value per Share|Net Assets per Single Share ADVB (Advanced Biomed Corp)|Genprex Inc. (GNPX) - Net Assets per Share|Accounting Value per Share calidibio.com CLDI|Sunshine Biopharma Inc. (SBFM) - Accounting Value of a Share|XBIO (Xenetic Biosciences Inc.) - Book Value per Share|Book Value per Share salariuspharma.com|PPBT: Book Value per Share|Book Value of One Share AONC (aoncology.com)|BeOne Medicines - Net Assets per Single Share|Checkpoint Therapeutics Inc - Accounting Value per Share|ELEV (Elevation Oncology, Inc.) - Net Assets per Single Share|ICAD: Net Asset Value per Share|Net Assets per Single Share ikenaoncology.com IKNA|Notable Labs Ltd (NTBL) - Accounting Value of a Share|Book Value per Share VIRX|Accounting Value per Share NAYA Biosciences Corp|Book Value per Share AAPGV